This inventor holds 1 USPTO granted patent. Top assignee: Celera Corporation. Active years: 2013.
Company Filing History:
Years Active: 2013
Title: Innovations by Robert J Lagier in Breast Cancer Prediction
Introduction
Robert J Lagier is an accomplished inventor based in San Leandro, CA (US). He has made significant contributions to the field of cancer research, particularly in predicting breast cancer metastasis. His innovative work has the potential to improve patient outcomes through more accurate risk assessments.
Latest Patents
Robert J Lagier holds a patent for a groundbreaking invention titled "Composite metastasis score with weighted coefficients for predicting breast cancer metastasis, and uses thereof." This invention relates to a composite metastasis score (cMS) that is based on the expression of a 14-gene molecular signature combined with progesterone receptor (PR) expression. The cMS is determined by applying weighted coefficients to the metastasis score and PR. This invention provides methods and reagents for detecting and profiling the expression levels of these genes, which can be instrumental in predicting the risk of breast cancer metastasis.
Career Highlights
Robert J Lagier is associated with Celera Corporation, where he has been able to apply his expertise in molecular biology and cancer research. His work at Celera has allowed him to collaborate with other leading scientists in the field, contributing to advancements in cancer diagnostics.
Collaborations
Some of his notable coworkers include Alice M Wang and Charles M Rowland. Their collaborative efforts have further enhanced the research and development of innovative solutions in cancer prediction.
Conclusion
Robert J Lagier's contributions to breast cancer research through his patent and work at Celera Corporation highlight the importance of innovation in medical science. His efforts in developing predictive tools for cancer metastasis are paving the way for improved patient care and treatment strategies.